open access

https://hdl.handle.net/2115/78746

High metabolic heterogeneity on baseline (18)FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma

英語

2020-05-26

American Society of Hematology

Blood Advances

4(10)

2286-2296

Metabolic heterogeneity (MH) can be measured using F-18-fluorodeoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline (18)FDG-PET/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL.

学術雑誌論文

Version of Record

2473-9529